A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-418 in Healthy Female Subjects
Latest Information Update: 04 Nov 2021
Price :
$35 *
At a glance
- Drugs TAK 418 (Primary)
- Indications Inborn genetic disorders
- Focus Adverse reactions
- Sponsors Takeda
- 14 May 2021 Results assessing safety, tolerability, pharmacokinetic and pharmacodynamic profiles of single and multiple doses of TAK-418 (NCT03228433 & NCT03501069), published in the British Journal of Clinical Pharmacology.
- 02 May 2019 Status changed from active, no longer recruiting to discontinued.
- 03 Dec 2018 Status changed from recruiting to active, no longer recruiting.